[Proton pump inhibitor for maintenance therapy of peptic ulcer].
The strategy for peptic ulcer therapy has been changing with the clinical application of the gastric proton pump inhibitor (PPI). In Japan, Miyoshi et al and Takemoto et al reported an earlier reepithelialization of peptic ulcer with omeprazole (OME) or lansoprazole (LAN) than famotidine (FAM). Miyoshi et al also reported that there was no significant difference between OME and FAM in ulcer relapse rate during a one year follow-up period. Therefore, there were two problems. One is application of PPI for prevention of ulcer relapse, and the other is the more accurate diagnosis of ulcer healing. Application of PPI for maintenance therapy is not yet realized in Japan, but, Lauritsen et al had already reported on the efficacy and safety of OME, 20 mg, three days a week and 10 mg, daily in prevention of duodenal ulcer relapse. Reepithelialization (red scar) is already established as a starting point of maintenance therapy, and from Miyake's report, a white scar is believed a favorable (non relapsing) end point.
Yanai
H
H
First Department of Internal Medicine, School of Medicine, Yamaguchi University.
Tada
M
M
Okita
K
K
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D016099:Endoscopy, Gastrointestinal; D017506:H(+)-K(+)-Exchanging ATPase; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000251:Adenosine Triphosphatases; D017506:H(+)-K(+)-Exchanging ATPase; D009853:Omeprazole